MX2023008629A - Nuevas nucleasas modificadas y quimericas. - Google Patents
Nuevas nucleasas modificadas y quimericas.Info
- Publication number
- MX2023008629A MX2023008629A MX2023008629A MX2023008629A MX2023008629A MX 2023008629 A MX2023008629 A MX 2023008629A MX 2023008629 A MX2023008629 A MX 2023008629A MX 2023008629 A MX2023008629 A MX 2023008629A MX 2023008629 A MX2023008629 A MX 2023008629A
- Authority
- MX
- Mexico
- Prior art keywords
- nucleases
- chimeric
- new modified
- chimeric nucleases
- genetically modified
- Prior art date
Links
- 101710163270 Nuclease Proteins 0.000 abstract 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03015—(S)-2-Hydroxy-acid oxidase (1.1.3.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140620P | 2021-01-22 | 2021-01-22 | |
| US202163237484P | 2021-08-26 | 2021-08-26 | |
| PCT/US2022/013396 WO2022159758A1 (en) | 2021-01-22 | 2022-01-21 | Novel engineered and chimeric nucleases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023008629A true MX2023008629A (es) | 2023-10-25 |
Family
ID=82549895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023008629A MX2023008629A (es) | 2021-01-22 | 2022-01-21 | Nuevas nucleasas modificadas y quimericas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230416710A1 (https=) |
| EP (1) | EP4281554A4 (https=) |
| JP (1) | JP2024504981A (https=) |
| KR (1) | KR20230134543A (https=) |
| AU (1) | AU2022210762A1 (https=) |
| BR (1) | BR112023014719A2 (https=) |
| CA (1) | CA3205865A1 (https=) |
| GB (1) | GB2610711B (https=) |
| MX (1) | MX2023008629A (https=) |
| WO (1) | WO2022159758A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2617658B (en) | 2020-03-06 | 2024-04-17 | Metagenomi Inc | Class II, type V CRISPR systems |
| CA3225082A1 (en) * | 2021-08-27 | 2023-03-02 | Brian C. Thomas | Enzymes with ruvc domains |
| WO2023178115A2 (en) * | 2022-03-14 | 2023-09-21 | Metagenomi, Inc. | Engineered and chimeric nucleases |
| CN119546757A (zh) | 2022-05-25 | 2025-02-28 | 宏基因组学公司 | 肝酶表达的补充 |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| EP4562138A2 (en) * | 2022-07-29 | 2025-06-04 | Metagenomi, Inc. | Class ii, type v crispr systems |
| WO2024156085A1 (en) * | 2023-01-27 | 2024-08-02 | Syngenta Crop Protection Ag | Mb2cas12a variants with enhanced efficiency |
| KR20250153814A (ko) * | 2023-03-01 | 2025-10-27 | 메타지노미, 인크. | Ruvc 도메인을 갖는 효소 |
| AU2024339645A1 (en) * | 2023-09-13 | 2026-04-23 | Metagenomi Therapeutics, Inc. | Engineered and chimeric nucleases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3363902B1 (en) * | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| US9963689B2 (en) * | 2013-12-31 | 2018-05-08 | The Regents Of The University Of California | Cas9 crystals and methods of use thereof |
| WO2016205759A1 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| JP2020536502A (ja) * | 2017-09-07 | 2020-12-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子操作のためのヌクレアーゼシステム |
| US12365888B2 (en) * | 2018-12-14 | 2025-07-22 | Pioneer Hi-Bred International, Inc. | CRISPR-Cas systems for genome editing |
| AU2020223370B2 (en) * | 2019-02-14 | 2023-04-20 | Metagenomi Therapeutics, Inc. | Enzymes with RuvC domains |
| US10913941B2 (en) * | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| KR20230021657A (ko) * | 2020-05-08 | 2023-02-14 | 메타지노미, 인크. | Ruvc 도메인을 포함하는 효소 |
| CA3192224A1 (en) * | 2020-09-11 | 2022-03-17 | Jyun-Liang LIN | Base editing enzymes |
| BR112023018948A2 (pt) * | 2021-03-19 | 2023-10-17 | Metagenomi Inc | Edição multiplex com enzimas cas |
| AU2022380842A1 (en) * | 2021-11-05 | 2024-05-23 | Metagenomi Therapeutics, Inc. | Base editing enzymes |
-
2022
- 2022-01-21 BR BR112023014719A patent/BR112023014719A2/pt unknown
- 2022-01-21 KR KR1020237028011A patent/KR20230134543A/ko active Pending
- 2022-01-21 AU AU2022210762A patent/AU2022210762A1/en active Pending
- 2022-01-21 JP JP2023544203A patent/JP2024504981A/ja active Pending
- 2022-01-21 GB GB2215621.0A patent/GB2610711B/en active Active
- 2022-01-21 EP EP22743281.2A patent/EP4281554A4/en active Pending
- 2022-01-21 WO PCT/US2022/013396 patent/WO2022159758A1/en not_active Ceased
- 2022-01-21 MX MX2023008629A patent/MX2023008629A/es unknown
- 2022-01-21 CA CA3205865A patent/CA3205865A1/en active Pending
- 2022-11-17 US US18/056,629 patent/US20230416710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2610711A (en) | 2023-03-15 |
| JP2024504981A (ja) | 2024-02-02 |
| US20230416710A1 (en) | 2023-12-28 |
| AU2022210762A1 (en) | 2023-08-24 |
| KR20230134543A (ko) | 2023-09-21 |
| EP4281554A4 (en) | 2025-06-18 |
| WO2022159758A1 (en) | 2022-07-28 |
| CA3205865A1 (en) | 2022-07-28 |
| AU2022210762A9 (en) | 2024-09-19 |
| GB2610711B (en) | 2023-08-02 |
| EP4281554A1 (en) | 2023-11-29 |
| BR112023014719A2 (pt) | 2023-12-05 |
| GB202215621D0 (en) | 2022-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008629A (es) | Nuevas nucleasas modificadas y quimericas. | |
| CL2024004045A1 (es) | Medios y método para preparar vectores virales y usos de los mismos | |
| CY1125029T1 (el) | Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων | |
| CL2018000302A1 (es) | Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas | |
| DOP2019000132A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO DE LAS MISMAS. | |
| CL2018003366A1 (es) | Anticuerpos anti -cd40 y sus usos | |
| CO2019003154A2 (es) | Anticuerpos anti-pd-1 y sus usos | |
| SA521421845B1 (ar) | منتجات مضادة للفيروسات وصيغ نانوية منها | |
| BR112017019591A2 (pt) | imunomodulares | |
| BR112017003718A2 (pt) | inibidores macrocíclicos das interações de proteína/proteína de pd-1/pd-l1 e cd80(b7-1)/pd-l1 | |
| EA201991369A1 (ru) | Модифицированные направляющие рнк | |
| MX394528B (es) | Esteroides y conjugados de proteinas de los mismos. | |
| MX2022013540A (es) | Constructos de expresion y metodos para dise?ar geneticamente levadura metilotrofica. | |
| MX2021008487A (es) | Escisión y poliadenilación del arn nuclear dirigido con crispr-cas. | |
| MX392031B (es) | Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2 | |
| UY37194A (es) | Inmunomoduladores | |
| BR112017012704A2 (pt) | imunomoduladores | |
| MX2017003847A (es) | Proteinas biespecificas activables por proteasas. | |
| AR105433A1 (es) | Métodos para mejorar la eficacia y expansión de las células inmunes | |
| AR105053A1 (es) | Inmunomoduladores | |
| CL2019002605A1 (es) | Formulaciones que contienen proteínas de unión pd-1 y métodos de fabricación de las mismas. | |
| MX2019008844A (es) | Ingenieria de celulas b. | |
| MX421249B (es) | Constructos de anticuerpos de ácidos nucleicos optimizados | |
| MX2020008801A (es) | Células presentadoras de antígeno universal y usos de las mismas. | |
| MX2019000189A (es) | Sistema de sujetador y costillas estabilizadoras. |